Cullinan Therapeutics, Inc. (CGEM)
| Market Cap | 1.26B +201.2% |
| Revenue (ttm) | n/a |
| Net Income | -208.34M |
| EPS | -3.47 |
| Shares Out | 64.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 675,991 |
| Open | 19.61 |
| Previous Close | 19.63 |
| Day's Range | 19.39 - 19.94 |
| 52-Week Range | 5.68 - 19.94 |
| Beta | -0.02 |
| Analysts | Strong Buy |
| Price Target | 31.73 (+61.89%) |
| Earnings Date | Aug 6, 2026 |
About CGEM
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for CGEM stock is "Strong Buy." The 12-month stock price target is $31.73, which is an increase of 61.89% from the latest price.
News
Cullinan Therapeutics reports Q2 EPS (81c), consensus (85c)
“At our recent Immunology Day event, we shared compelling initial clinical data for CLN-978 and velinotamig, two T cell engagers with potential to achieve immune reset and transform outcomes for…
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027
Cullinan Therapeutics Quarterly report: Q2 2026
Cullinan Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Cullinan Therapeutics Earnings release: Q2 2026
Cullinan Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Cullinan Therapeutics price target raised to $39 from $38 at BTIG
BTIG raised the firm’s price target on Cullinan Therapeutics (CGEM) to $39 from $38 and keeps a Buy rating on the shares. The firm notes that CLN-049 is advancing to…
Cullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA
Cullinan Therapeutics (CGEM) announced feedback from the FDA following an End-of-Phase 1 meeting for CLN-049, a FLT3xCD3 T cell engager being evaluated in patients with acute myeloid leukemia. The EOP...
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, d...
Cullinan Therapeutics management to meet with BTIG
Biotechnology Analyst Harrison holds a group dinner meeting with management in New York on July 21 at 5:30 pm hosted by BTIG.
Cullinan Therapeutics price target raised to $46 from $33 at Clear Street
Clear Street raised the firm’s price target on Cullinan Therapeutics (CGEM) to $46 from $33 and keeps a Buy rating on the shares. CLN-978’s initial Phase 1 data, including remissions…
Cullinan Therapeutics Transcript: Immunology Day 2026
CLN-978 and velinotamig, two T-cell engagers, showed strong efficacy and safety in refractory autoimmune diseases, achieving deep B-cell and antibody depletion and clinical remission. Multi-dose and tissue data support immune reset, with phase II studies and regulatory milestones planned for 2027.
Cullinan Therapeutics Slides: FY 2026
Cullinan Therapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 10, 2026.
Cullinan Therapeutics Press release: FY 2026
Cullinan Therapeutics issued a press release on June 10, 2026, disclosing material business information to investors.
Cullinan Therapeutics reports CLN-978, velinotamig data
Cullinan Therapeutics (CGEM) reported clinical data and outlined global clinical development plans for CLN-978, a CD19xCD3 T cell engager, and velinotamig, a BCMAxCD3 T cell engager. New multi-dose da...
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)
Cullinan Therapeutics presents clinical data for CLN-978
Cullinan Therapeutics (CGEM) announced that it will present initial clinical data from two ongoing Phase 1 studies of CLN-978, a CD19xCD3 T cell engager, at the European Alliance of Associations…
Cullinan to host Immunology Day event, announce data for CLN-978, Velinotamig
Cullinan Therapeutics (CGEM) announced that the Company will host an in-person Immunology Day event in New York City for analysts and institutional investors. Key information to be presented includes:...
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies Initial data from the first multi-dose cohort of RA...
Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street
Clear Street reiterated a Buy rating and $33 price target on Cullinan Therapeutics (CGEM), saying the firm views the post-EULAR share pullback after release of the CLN-978 Phase 1 abstract…
Cullinan Therapeutics receives orphan drug designation for CLN-049
Cullinan Therapeutics (CGEM) announced that the FDA has granted orphan drug designation to CLN-049, a novel, investigational FLT3xCD3 T cell engager, for the treatment of relapsed/refractory acute mye...
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact t...
Cullinan Therapeutics price target raised to $37 from $36 at Wedbush
Wedbush raised the firm’s price target on Cullinan Therapeutics (CGEM) to $37 from $36 and keeps an Outperform rating on the shares. The firm notes the company reported first quarter…
Cullinan Therapeutics reports Q1 EPS (75c), consensus (85c)
“T cell engagers have the potential to transform outcomes for people living with autoimmune diseases and cancer, and emerging clinical data underscore their promise as a compelling therapeutic modalit...
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for rela...
Cullinan Therapeutics Quarterly report: Q1 2026
Cullinan Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.